Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00027586 · ClinicalTrials.gov registry record · Phase 2

Imatinib Mesylate in Treating Patients With Metastatic Melanoma

A Phase 2 study, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
22
Enrollment target

NCT00027586: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.

NCT00027586 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00027586, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
22 participants
Enrollment target

Study Summary

RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma.

Interventions

  • DRUG Imatinib mesylate (STI571)

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2001-09
Est. Completion 2005-01
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT00027586 record still lists

NCT00027586 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).

The record links to 0 conditions, and to 1 intervention - of which Imatinib mesylate (STI571) is the first listed.

NCT00027586 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00027586 about?

NCT00027586 is a clinical study titled "Imatinib Mesylate in Treating Patients With Metastatic Melanoma". RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma.

What is the current status of trial NCT00027586?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2001-09. Estimated completion is 2005-01.

What interventions are being tested in trial NCT00027586?

The interventions under investigation include: Imatinib mesylate (STI571) (DRUG).

Who is sponsoring clinical trial NCT00027586?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00027586's enrollment target sits among peer trials

22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00027586, the US trial registry maintained by the National Library of Medicine. NCT00027586 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.